<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678704</url>
  </required_header>
  <id_info>
    <org_study_id>100607</org_study_id>
    <nct_id>NCT00678704</nct_id>
  </id_info>
  <brief_title>BAY38-9456 - Pivotal Trial for Diabetes Patient</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind, Multi-centre, Parallel Group Study to Investigate the Efficacy and Safety of BAY 38-9456 in Males With Diabetes Suffering From Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The superiority of BAY 38-9456 10 mg and 20 mg regimens to placebo, and of 20 mg to 10 mg was
      confirmed in patients with diabetes mellitus suffering from erectile dysfunction. There was
      no large difference in incidence rate of drug-related adverse events between 10 mg and 20 mg
      regimens. Overall the tolerability was considered good with both regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Erectile Function (EF) domain score of IIEF calculated as the sum of scores from Questions 1 to 5 and 15</measure>
    <time_frame>At 12 weeks after start of study drug administration using data at LOCF to account for dropouts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Global Assessment Question</measure>
    <time_frame>At 4, 8, 12 weeks after start of study drug administration and LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The IIEF EF domain score</measure>
    <time_frame>At 4, 8, 12 weeks after start of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF domain scores other than the EF domain score[intercourse satisfaction (Q6 to Q8), overall satisfaction (Q13, Q14), orgasmic function (Q9, Q10), sexual desire (Q11, Q12)]</measure>
    <time_frame>At 4, 8, 12 weeks after start of study drug administration and LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of Questions 1 to 15 on the IIEF Questionnaire</measure>
    <time_frame>At 4, 8, 12 weeks after start of study drug administration and LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's diary response concerning hardness of erection, maintenance of erection, satisfaction with overall hardness of erection, ability of insertion, overall satisfaction with sexual experience and ejaculation</measure>
    <time_frame>At 4, 8, 12 weeks after start of study drug administration and LOCF</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">790</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levitra (Vardenafil, BAY38-9456)</intervention_name>
    <description>BAY 38-9456 10 mg tablet prior to intercourse on demand</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levitra (Vardenafil, BAY38-9456)</intervention_name>
    <description>BAY 38-9456 20 mg tablet prior to intercourse on demand</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet prior to intercourse on demand</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male with erectile dysfunction for more than 3 years according to the National
             Institutes of Health (NIH) Consensus Statement (inability to attain and/or maintain
             penile erection sufficient for satisfactory sexual performance)

          -  Diabetes for more than 3 years

        Exclusion Criteria:

          -  Following to the labeling of Japanese package insert for vardenafil 5/10 mg, except
             for the highest dose

          -  Spinal cord injury

          -  History of surgical prostatectomy (excluding TURP)

          -  Patients with an HbA1c &gt; 12% at Visit 1

          -  Use of nitrates

          -  Use of potent CYP3a4 inhibitors

          -  Severe liver disease

          -  Presence of Peyronie's Disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vardenafil</keyword>
  <keyword>PDE5 inhibitor</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Sexual Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vardenafil Dihydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

